In our cohort, SSTR2A expression was significantly associated with oligodendrogliomas (79% SSTR2A positive) compared to IDH-mutant or IDH-wildtype astrocytomas (27% and 23%, respectively) and especially glioblastomas of which only 13% were SSTR2A positive. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).